Xvivo Perfusion ABXVIPF -1.32%91 EBITDA Margin % is 13.26% as of Mar. 2026, which is 13% below its 10-year median of 15.16. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 58.09% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Xvivo Perfusion AB's EBITDA for the
three
months ended in Mar. 2026 was $3.43 Mil. Xvivo Perfusion AB's Revenue for the
three
months ended in Mar. 2026 was $25.86 Mil. Therefore, Xvivo Perfusion AB's EBITDA margin for the quarter that ended in Mar. 2026 was 13.26%.
Xvivo Perfusion AB (OTCPK:XVIPF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Xvivo Perfusion AB EBITDA Margin % Related Terms
Xvivo Perfusion AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XVIPF vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a EBITDA Margin % of 13.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xvivo Perfusion AB and its competitors. This is 13% below median its historical median of 15.16. According to the industry distribution chart, Xvivo Perfusion AB ranks #342 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 41.9%.
Is Xvivo Perfusion AB's EBITDA Margin % too high?
Xvivo Perfusion AB's current EBITDA Margin % of 13.26% is 13% below median its 10-year median of 15.16. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Xvivo Perfusion AB's value of 13.26% is 77.4% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #342 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #342 out of 816 companies for EBITDA Margin %. This puts Xvivo Perfusion AB in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Xvivo Perfusion AB's value of 13.26% is 77.4% above this benchmark. While the company's 10-year median is 15.16 vs. the industry median of 7.48, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current EBITDA Margin % of 13.26% is 77.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current EBITDA Margin % is 13.26%, which is 13% below median its own 10-year median of 15.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current EBITDA Margin % is 13.26%, which is 13% below median its 10-year median of 15.16 and 77.4% above the Medical Devices & Instruments industry median of 7.48. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current EBITDA Margin % is 13.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
EBITDA Margin %: 13.26% (13% below median its 10-year median of 15.16)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 77.4% above the Medical Devices & Instruments median (#342 of 816)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
